ClinicalTrials.gg
CompletedNCT07838662TRAM-MAGSUpdated Sep 24, 2026

Prophylactic Tramadol Versus Magnesium Sulphate for Prevention of Post-Spinal Shivering

An interventional study of Tramadol and Magnesium Sulphate in Post-spinal Shivering, sponsored by Punjab Rangers Teaching Hospital Lahore. Completed at 1 site in Pakistan. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Punjab Rangers Teaching Hospital Lahore · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled Oct 2024, registered Sep 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

This randomized controlled trial compared prophylactic intravenous tramadol and magnesium sulphate for the prevention of post-spinal shivering among women undergoing elective cesarean section under spinal anesthesia. The study was conducted in the Department of Anaesthesia, Punjab Rangers Teaching Hospital, Lahore, over six months from 10 October 2024 to 10 April 2025.

A total of 106 pregnant women aged 18-40 years were enrolled following ethical approval, informed consent, and counseling. Participants were randomly allocated into two equal groups (n=53 each). Group A received tramadol 0.5 mg/kg intravenously, while Group B received magnesium sulphate 30 mg/kg intravenously. Both drugs were diluted in 100 mL isotonic saline and administered after spinal anesthesia. Standardized anesthetic techniques, perioperative monitoring, operating-room temperature, fluid co-loading, and postoperative observation were maintained.

Patients with major cardiopulmonary, renal, or hepatic disease, thyroid disorders, pre-eclampsia, eclampsia, psychiatric illness, morbid obesity, significant blood transfusion or fluid administration, abnormal placental attachment, or relevant drug allergies were excluded.

Spinal anesthesia was performed using 0.5% hyperbaric bupivacaine at the L3-L4 or L4-L5 interspace. Patients were monitored using ECG, non-invasive blood pressure, pulse oximetry, pulse rate, and temperature monitoring. Post-spinal shivering was defined as involuntary muscle activity lasting more than 15 seconds with a Crossley and Mahajan score of ≥2. The occurrence and severity of shivering were assessed, and adverse effects including nausea, vomiting, bradycardia, arrhythmia, and hypotension were recorded. Shivering was managed with warming, oxygen supplementation, or rescue medication when required.

The primary outcome was the incidence of post-spinal shivering. Secondary outcomes included shivering severity and adverse effects. Data were analyzed using SPSS version 26. Continuous variables were assessed for distribution and summarized as mean ± standard deviation, while categorical variables were presented as frequencies and percentages. Between-group comparisons were performed using the independent-samples t-test for continuous variables where appropriate and the chi-square test or Fisher's exact test for categorical variables, according to expected cell frequencies. The primary outcome and other categorical outcomes were analyzed using chi-square or Fisher's exact test as appropriate. A two-sided p-value of ≤0.05 was considered statistically significant.

Read the detailed description

This randomized controlled trial was conducted to compare the effectiveness of prophylactic intravenous tramadol with intravenous magnesium sulphate for prevention of post-spinal shivering in women undergoing elective cesarean section under spinal anesthesia. The study was conducted in the Department of Anaesthesia, Punjab Rangers Teaching Hospital, Lahore, over a period of six months from 10 October 2024 to 10 April 2025.

Spinal anesthesia is widely used for cesarean section because of its rapid onset, reliability, avoidance of airway manipulation, and favorable maternal and neonatal safety profile. However, post-spinal shivering is a relatively common complication and may cause considerable discomfort and anxiety for the patient. Shivering may also interfere with monitoring and may increase oxygen consumption and metabolic demand. Various pharmacological agents have therefore been investigated for prevention and treatment of shivering associated with neuraxial anesthesia. Tramadol has been used as an anti-shivering agent because of its central effects on serotonergic and noradrenergic pathways, while magnesium sulphate may reduce shivering by influencing neuromuscular transmission and lowering the shivering threshold. Previous comparative studies have reported conflicting results regarding the effectiveness of these agents in patients undergoing cesarean section under spinal anesthesia. The present study was therefore undertaken to compare the two agents under standardized perioperative conditions.

A total of 106 pregnant women scheduled for elective cesarean section were enrolled after obtaining ethical approval and written informed consent. Eligible participants were women aged 18 to 40 years undergoing elective cesarean section under spinal anesthesia. Participants were selected through non-probability consecutive sampling. Patients were excluded if they had severe systemic disease involving the cardiopulmonary, renal, or hepatic systems; thyroid disorders; pre-eclampsia or eclampsia; psychiatric illness; morbid obesity; significant intraoperative blood transfusion or excessive fluid administration; abnormal placental attachment; or allergy to any of the study medications.

After enrollment, participants were randomly allocated into two equal groups of 53 patients each. Group A received tramadol at a dose of 0.5 mg/kg intravenously, while Group B received magnesium sulphate at a dose of 30 mg/kg intravenously. In both groups, the assigned study medication was diluted in 100 mL isotonic saline and administered after establishment of spinal anesthesia. Standardized drug doses and similar perioperative conditions were used to ensure comparability between the treatment groups.

All participants received standard preoperative medications and anesthetic management according to the institutional protocol. Preoperative medications included oral ranitidine 150 mg and metoclopramide 10 mg on the night before surgery, with intravenous medications administered before anesthesia as per protocol. Spinal anesthesia was performed in the sitting position using a 25- or 26-gauge Quincke needle at the L3-L4 or L4-L5 intervertebral level. A dose of 2.0-2.2 mL of 0.5% hyperbaric bupivacaine was used for the spinal block. Ringer lactate was administered as a co-load at 10 mg/kg according to the study protocol. The operating-room temperature was maintained at approximately 24-25°C.

Standard monitoring was applied throughout the perioperative period, including electrocardiography, non-invasive blood pressure, pulse oximetry, pulse rate, and temperature monitoring. A senior consultant supervised the anesthetic procedures. Data collection was performed by the resident responsible for assessment and documentation according to the study proforma. Standardized anesthesia and monitoring protocols were used in both groups to minimize potential confounding.

The primary outcome was the occurrence of post-spinal shivering after administration of the study medication. Shivering was defined as involuntary, spontaneous muscular activity lasting for more than 15 seconds and reaching a score of 2 or higher on the Crossley and Mahajan shivering scale. The presence or absence of shivering was recorded during the observation period. In patients who developed shivering, the grade of shivering was documented. The severity categories included Grade II, Grade III, and Grade IV in accordance with the scale used in the study.

Secondary assessments included the severity of post-spinal shivering and the occurrence of perioperative adverse effects. Adverse effects monitored during the study included nausea, vomiting, bradycardia, arrhythmia, and hypotension. Patients who developed shivering were managed according to the institutional clinical protocol, including external warming, oxygen supplementation, and rescue pharmacological treatment such as pethidine or dexmedetomidine when clinically indicated.

Baseline demographic and clinical characteristics were recorded for all participants, including age, body mass index (BMI), American Society of Anesthesiologists (ASA) physical status, and parity. Age was categorized into 18-30 years and 31-40 years for subgroup analysis. BMI was categorized into normal-weight and overweight/obese groups. ASA physical status was categorized as ASA-I or ASA-II. Parity was categorized as parity ≤2 or >2.

The sample size was calculated using the WHO sample size calculator with an assumed statistical power of 80% and a significance level of 5%. The calculation was based on previously reported shivering frequencies of 7.7% in patients receiving tramadol and 30.8% in patients receiving magnesium sulphate. The resulting sample consisted of 106 participants, with 53 participants allocated to each treatment group.

Data were entered, coded, and analyzed using SPSS version 26. Continuous variables were assessed for distribution and summarized as mean ± standard deviation, while categorical variables were presented as frequencies and percentages. Baseline demographic and clinical characteristics were compared between the two groups to assess their comparability. The independent-samples t-test was used for comparison of continuous variables where appropriate. The chi-square test was used for comparison of categorical variables, while Fisher's exact test was applied where expected cell frequencies were small. The primary outcome, occurrence of post-spinal shivering, was compared between the two treatment groups using the chi-square or Fisher's exact test, as appropriate. Shivering severity grades and perioperative adverse effects were also compared between groups using appropriate categorical tests. A two-sided p-value of ≤0.05 was considered statistically significant.

Stratified analysis was performed to assess whether the frequency of post-spinal shivering varied according to important baseline characteristics. Comparisons were stratified by age, BMI, ASA physical status, and parity. The chi-square test or Fisher's exact test was applied as appropriate within each subgroup. All statistical tests were two-sided, and a p-value of ≤0.05 was considered statistically significant.

02

Conditions studied

  • Post-spinal Shivering

Keywords

  • Magnesium Sulfate, Tramadol, Shivering, Anesthesia Spinal
03

In context

Lead sponsor

Punjab Rangers Teaching Hospital Lahore is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women between 18 and 40 years age and undergoing elective cesarean section will be enrolled in the study.

Exclusion criteria

Exclusion Criteria:

  • Patients with severe cardiopulmonary, renal, or liver disease, pre-eclampsia, eclampsia, hypo- or hyperthyroidism.
  • Patients with psychiatric disorders or morbid obesity.
  • Patients who have received blood transfusion or >2,000 mL fluid intraoperatively.
  • Patients with placenta accreta or placenta percreta.
  • Patients allergic to either study drug.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Tramadol Group

    Participants in this group received prophylactic intravenous tramadol at a dose of 0.5 mg/kg after administration of spinal anesthesia. The drug was diluted in 100 mL isotonic saline and administered according to the study protocol. Standardized spinal anesthesia, perioperative monitoring, operating-room temperature, fluid co-loading, and postoperative observation were provided. Post-spinal shivering was assessed using the Crossley and Mahajan scale, and its occurrence and severity were recorded.

    Drug: Tramadol

  • Active comparator
    Magnesium Sulphate Group

    Participants in this group received prophylactic intravenous magnesium sulphate at a dose of 30 mg/kg after administration of spinal anesthesia. The drug was diluted in 100 mL isotonic saline and administered according to the study protocol. Standardized spinal anesthesia, perioperative monitoring, operating-room temperature, fluid co-loading, and postoperative observation were provided. Post-spinal shivering was assessed using the Crossley and Mahajan scale, and its occurrence and severity were recorded.

    Drug: Magnesium Sulphate

Interventions

  • Tramadol 0.5 mg/kg intravenously in 100 mL isotonic saline after spinal anesthesia for prevention of post-spinal shivering.

    Also known as: Tramadol HCl

  • DrugMagnesium SulfateStudies of Magnesium SulfateMagnesium Sulfate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Magnesium sulphate 30 mg/kg intravenously in 100 mL isotonic saline after spinal anesthesia for prevention of post-spinal shivering.

    Also known as: MgSO₄

06

What researchers measure

Primary outcomes

  1. Incidence of post-spinal shivering

    Occurrence of post-spinal shivering following spinal anesthesia, defined as involuntary spontaneous muscle hyperactivity lasting more than 15 seconds with a Crossley and Mahajan shivering scale score ≥2.

    Time frame: From administration of spinal anesthesia until the end of the surgical procedure-Last Stitch

Secondary outcomes

  1. Severity of post-spinal shivering

    Severity of shivering assessed using the Crossley and Mahajan shivering scale and categorized as Grade II, Grade III, or Grade IV among participants who developed shivering.

    Time frame: From administration of spinal anesthesia until the end of the surgical procedure-Last Stitch

Other outcomes

  1. Adverse effects

    Occurrence of treatment-related adverse effects, including nausea, vomiting, bradycardia, arrhythmia, and hypotension.

    Time frame: From administration of the study drug until the end of the intraoperative observation period.

07

Study locations

1 site
  • Department of Anaesthesia
    Lahore, Punjab Province 54810, Pakistan
08

References and documents

Publications

  • 1. Esmat IM, Mohamed MM, Abdelaal WA, El-Hariri HM, Ashoor TM. Postspinal anesthesia shivering in lower abdominal and lower limb surgeries: a randomized controlled comparison between paracetamol and dexamethasone. BMC Anesthesiol. 2021; 21:1-3. doi: 10.1186/s12871-021-01483-7. 2. Paliwal N, Khan IA, Paliwal Sr N. Exploring variability in spinal anesthesia levels achieved during cesarean section deliveries: a narrative review. Cureus 2025;17(7):e88429. doi: 10.7759/cureus.88429. 3. Jouryabi AM, Sharami SH, Ghanaie MM, Sedighinejad A, Imantalab V, Sorouri, ZR, et al. Comparing the effects of low dose of ketamine, tramadol, and ondansetron in prevention of post spinal anesthesia shivering in cesarean section. Anesth Pain Med. 2021; 11(4):e116429. doi: 10.5812/aapm.116429. 4. Kanchan S, Shah AM, Shah A, Sameen Z, Arya A, Riaz S, et al. Post spinal anaesthesia shivering-incidence and associated risk factors in patients undergoing lower limb and abdominal surgeries. Int J Res Med Sci. 2022; 10(10):2285-90. doi: 10.18203/2320-6012.ijrms20222536. 5. Qi X, Chen D, Li G, Cao J, Yan Y, Li Z, et al. Risk factors associated with intraoperative shivering during caesarean section: a prospective nested case-control study. BMC Anesthesiol. 2022; 22(1):56. doi: 10.1186/s12871-022-01596-7. 6. Feng G, Wang Y, Feng J, Luo X, Li C, Yao S. The relationship between core temperature and perioperative shivering during caesarean section under intrathecal anesthesia with bupivacaine and ropivacaine: a randomized controlled study. J Anesth. 2021; 35(6):889-95. doi: 10.1007/s00540-021-02995-9. 7. Low RG, Izaham A, Zain JM, Nor NM, Low HJ, Yusof AM. Prevention of shivering post subarachnoid block: comparison between different doses of intravenous magnesium sulphate. Medicina. 2022;58(8):1046. doi:10.3390/medicina58081046. 8. Pryambodho, Manggala SK, Sihombing M. Intravenous magnesium sulfate versus intravenous meperidine to prevent shivering during spinal anesthesia. Med J Indones. 2022; 31(2):1

Individual participant data

Plan to share: No — Individual participant-level data (IPD) will not be shared with other researchers because no data-sharing plan was established as part of this study. The study data were collected for the stated research objectives and are maintained by the investigators. Participant confidentiality and privacy will be protected, and individual-level information will not be made publicly available. Only aggregate, de-identified results are reported in the manuscript.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Oct 2025, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2026
First posted
Sep 24, 2026
StartActual
Oct 10, 2024
Primary completionActual
Oct 10, 2025
CompletionActual
Oct 10, 2025
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07838662
Lead sponsor
Punjab Rangers Teaching Hospital Lahore
Responsible party
Ayesha Jamal (Dr., Punjab Rangers Teaching Hospital Lahore) — Principal investigator
First posted
Sep 24, 2026
Start date
Oct 10, 2024
Primary completion
Oct 10, 2025
Completion
Oct 10, 2025
Last update
Sep 24, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tramadol

Start the discussion